Published in BMJ on April 25, 1998
Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol (2004) 2.32
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol (2001) 1.77
Consultations owing to adverse drug reactions in a single practice. Br J Gen Pract (2001) 1.65
Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc (2012) 1.43
Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009. J R Soc Med (2010) 1.36
Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Ther Adv Drug Saf (2013) 1.35
Antidepressants and violence: problems at the interface of medicine and law. PLoS Med (2006) 1.28
Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol (2006) 1.27
Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. J Am Med Inform Assoc (2012) 1.10
Pharmacogenomics of adverse drug reactions. Genome Med (2013) 1.00
Adverse drug reactions: back to the future. Br J Clin Pharmacol (2003) 1.00
Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol (2005) 0.98
The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol Sci (2007) 0.97
Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J (2005) 0.96
A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital. Saudi Pharm J (2014) 0.94
Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open (2014) 0.93
Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch (2011) 0.87
Adverse drug reactions in internal medicine units and associated risk factors. Eur J Clin Pharmacol (2010) 0.85
Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital. J Pharmacol Pharmacother (2012) 0.85
Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease. Indian J Pharmacol (2011) 0.84
A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. Int J Pharm Pract (2015) 0.83
Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. J Med Ethics (2005) 0.83
Aripiprazole induced severe and extensive skin reaction: A case report. Ther Adv Psychopharmacol (2012) 0.82
Age-related differences in susceptibility to cisplatin-induced renal toxicity. J Appl Toxicol (2010) 0.82
Monitoring medicines use: the role of the clinical pharmacologist. Br J Clin Pharmacol (2012) 0.81
Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice. Drug Metab Dispos (2014) 0.80
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood (2016) 0.79
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet (2016) 0.78
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol (2000) 0.78
Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implement Sci (2015) 0.78
Are primary care factors associated with hospital episodes for adverse drug reactions? A national observational study. BMJ Open (2015) 0.78
New insights into drug metabolism and toxicology report of a symposium on drug metabolism and toxicity held at the British Pharmacological Society Meeting in Cardiff, UK, in July 2000. Br J Clin Pharmacol (2001) 0.78
Prevalence and assessment of factors contributing to adverse drug reactions in wards of a tertiary care hospital, India. Ethiop J Health Sci (2013) 0.77
Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice. Clin Vaccine Immunol (2006) 0.77
Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip Toxicol (2013) 0.77
Clinical pharmacy in primary care. Br J Clin Pharmacol (1998) 0.75
Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharmacol (2016) 0.75
Drug allergy: causes and desensitization. Hum Vaccin Immunother (2012) 0.75
Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. Br J Clin Pharmacol (2015) 0.75
Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Drug Saf (2017) 0.75
Self-reported medication side effects in an older cohort living independently in the community--the Melbourne Longitudinal Study on Healthy Ageing (MELSHA): cross-sectional analysis of prevalence and risk factors. BMC Geriatr (2010) 0.75
Paediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countries. PLoS One (2014) 0.75
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. Int J Nanomedicine (2016) 0.75
A Review of Pharmacovigilance. West Indian Med J (2015) 0.75
Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ (2017) 0.75
Supporting prescribing in older people with multimorbidity and significant polypharmacy in primary care (SPPiRE): a cluster randomised controlled trial protocol and pilot. Implement Sci (2017) 0.75
Discovering adverse drug events combining spontaneous reports with electronic medical records: a case study of conventional DMARDs and biologics for rheumatoid arthritis. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. Saudi Pharm J (2016) 0.75
Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol (2017) 0.75
Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients. Eur J Clin Pharmacol (2017) 0.75
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA (1995) 26.38
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 14.57
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 13.66
Liver failure induced by paracetamol. BMJ (1993) 8.18
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med (1995) 5.98
Drug-related hospital admissions. Ann Pharmacother (1993) 4.91
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond (1995) 4.55
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Towards the safer use of medicines. BMJ (1995) 3.50
Adverse reactions to co-trimoxazole in HIV infection. Lancet (1991) 3.16
Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet (1989) 3.01
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA (1993) 2.98
Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis (1990) 2.54
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem (1996) 2.25
Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys (1989) 1.89
Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology (1995) 1.54
Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy (1988) 1.47
Drug disposition and drug hypersensitivity. Biochem Pharmacol (1987) 1.46
Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut (1988) 1.39
Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A (1996) 1.28
Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol (1992) 1.13
Medication-related adverse reactions and the elderly: a literature review. Adverse Drug React Toxicol Rev (1995) 1.11
The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol (1988) 1.09
CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol (1991) 1.06
Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS (1995) 1.02
The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther (1995) 1.01
Drug-induced allergic hepatitis. Semin Liver Dis (1990) 0.93
Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol (1994) 0.91
Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis. Ann N Y Acad Sci (1993) 0.89
The role of active metabolites in drug toxicity. Drug Saf (1994) 0.87
Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS (1996) 0.86
Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet (1996) 0.85
Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions? Drug Saf (1993) 0.83
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Cimetidine: interaction with oral anticoagulants in man. Lancet (1979) 4.67
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci (2000) 2.98
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
4-Aminoquinolines--past, present, and future: a chemical perspective. Pharmacol Ther (1998) 2.00
Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol (2001) 1.97
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem (1978) 1.90
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J (2006) 1.87
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
Rifampicin and vitamin D metabolism. Clin Pharmacol Ther (1980) 1.78
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol (1989) 1.71
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (1997) 1.65
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
Differential detection of transmissible gastroenteritis virus and porcine epidemic diarrhea virus by duplex RT-PCR. J Vet Diagn Invest (2001) 1.59
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther (1981) 1.52
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. Vaccine (2003) 1.47
Drug disposition and drug hypersensitivity. Biochem Pharmacol (1987) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
Isolation and phylogenetic analysis of H1N1 swine influenza virus isolated in Korea. Virus Res (2006) 1.45
Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol (1981) 1.45
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 1.43
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS (1996) 1.41
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol (1978) 1.40
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs (1981) 1.36
Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol (2003) 1.35
4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem (1996) 1.35
Interindividual differences in the response to oral anticoagulants. Drugs (1977) 1.34
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
The burden of alcohol misuse on an inner-city general hospital. QJM (2000) 1.31
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.30
Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. Clin Sci Mol Med (1977) 1.30
An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol (1988) 1.29
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol (1985) 1.27
Application of scanning electron microscopy in assessing the prevalence of some Setaria species in Korean cattle. Korean J Parasitol (1994) 1.27
Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol (1989) 1.27
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol (1986) 1.26
Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol (1981) 1.26
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol (1980) 1.21
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol (1990) 1.21
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother (1995) 1.21
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1984) 1.19
Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element. J Virol (1995) 1.19
Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg (1991) 1.19
Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol (1984) 1.19
One-step multiplex RT-PCR for detection and subtyping of swine influenza H1, H3, N1, N2 viruses in clinical samples using a dual priming oligonucleotide (DPO) system. J Virol Methods (2008) 1.18
Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol (1983) 1.17
High-performance liquid chromatographic analysis of amodiaquine in human plasma. J Chromatogr (1985) 1.17
Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm (1976) 1.16
Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia. Lancet (1973) 1.15
Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol Biochem Parasitol (1996) 1.15
Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. Br J Clin Pharmacol (1991) 1.14
Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol (2000) 1.13
Effect of chloroquine and primaquine on antipyrine metabolism. Br J Clin Pharmacol (1983) 1.13
Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol (1992) 1.13
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol (1983) 1.13
Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med (1986) 1.12
Interspecies transmission of the canine influenza H3N2 virus to domestic cats in South Korea, 2010. J Gen Virol (2011) 1.10
The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception (1983) 1.10
A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol (1982) 1.10
Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther (1982) 1.10
The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. Contraception (1981) 1.09
Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem Pharmacol (1983) 1.09
Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. Br J Pharmacol (1998) 1.09
Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther (1978) 1.09
A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol (1988) 1.09
Drug interactions with warfarin. Drugs (1983) 1.09
Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings]. Br J Clin Pharmacol (1978) 1.09
In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol (1990) 1.08
The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol (1982) 1.08
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol (1988) 1.07
Assessment of new drugs: a clinical pharmacologist's view. Br Med J (1980) 1.07
Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet (1988) 1.06
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther (2012) 1.06
Difenacoum (Neosorexa) poisoning. Br Med J (Clin Res Ed) (1982) 1.06